METHODS AND COMPOSITIONS FOR PROTECTIVE AND THERAPEUTIC GENETIC IMMUNIZATION

(19)

(11)

EP 0 882 134 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	02.09.2009 Bulletin 2009/36

(45)	Mention of the grant of the patent:
	22.04.2009 Bulletin 2009/17

(21)	Application number: 97906764.2

(22)	Date of filing: 20.02.1997

(51)

International Patent Classification (IPC):

C12N 15/86^(2006.01)
C12N 7/04^(2006.01)
C07K 14/16^(2006.01)
C12N 5/06^(2006.01)

A61K 48/00^(2006.01)
C12N 15/19^(2006.01)
C12N 5/10^(2006.01)
A61K 51/12^(2006.01)

(86)	International application number:
	PCT/US1997/002933

(87)	International publication number:
	WO 1997/031119 (28.08.1997 Gazette 1997/37)

(54)	METHODS AND COMPOSITIONS FOR PROTECTIVE AND THERAPEUTIC GENETIC IMMUNIZATION VERFAHREN UND ZUSAMMENSETZUNGEN ZUR GENETISCH SCHÜTZENDEN UND THERAPEUTISCHEN IMMUNISIERUNG PROCEDES ET COMPOSITIONS POUR L'IMMUNISATION GENETIQUE PROTECTRICE ET THERAPEUTIQUE

(84)	Designated Contracting States:
	AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
	Designated Extension States:
	AL LT LV RO SI

(30)

Priority:

21.02.1996 US 604627

(43)	Date of publication of application:
	09.12.1998 Bulletin 1998/50

(73)	Proprietor: Genetic Immunity kft.
	Budapest 1045 (HU)

(72)	Inventors:
	LISZIEWICZ, Julianna H-1045 Budapest (HU) LORI, Franco H-1045 Budapest (HU)

(74)	Representative: Jones, Helen M.M.
	Gill Jennings & Every LLP Broadgate House 7 Eldon Street London EC2M 7LH London EC2M 7LH (GB)

(56)

References cited: :

WO-A-92/20356
WO-A1-94/24267

WO-A-96/06177

GENE THERAPY OF CANCER : 2ND EUROPEAN CONFERENCE, LONDON, UK, SEPTEMBER 7-8 1995 HEEMSKERK, MHM et al.: "Melanoma-specific CTL, generated in viro using dendritic cells expressing melanoma associated antigens". Page A13 XP000675471
JOURNAL OF IMMUNOLOGY, vol. 154, May 1995, BALTIMORE US, pages 4685-4692, XP000676343 WANG, M. ET AL.: "Active immunotherapy of cancer with a nonreplicating recombinant Fowlpox Virus encoding a model tumor-associated antigen"
TRANSPLANTATION, vol. 59, no. 4, 27 February 1995, pages 544-551, XP000675701 THOMSON, A.W. ET AL.: "In vitro propagation and homing of liver-derived dendritic cell progenitors to lymphoid tissues of allogeneic recipients"
AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 9, no. SUPPL. 01, 1 October 1993, page S33 XP000560222 KLEIN M ET AL: "DEVELOPMENT OF A CROSS-NEUTRALIZING HIV-1 PSEUDOVIRION-BASED VACCINE"
JOURNAL OF VIROLOGY, vol. 69, no. 1, 1 January 1995, pages 376-386, XP000560257 WISKERCHEN M ET AL: "HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INTEGRASE: EFFECTS OF MUTATIONS ON VIRAL ABILITY TO INTEGRATE, DIRECT VIRAL GENE EXPRESSION FROM UNINTEGRATED VIRAL DNA TEMPLATES, AND SUSTAIN VIRAL PROPAGATION IN PRIMARY CELLS"
LISZIEWICZ J. ET AL.: 'induction of potent human immunodeficiency virus type 1 specific T-cell restricted immunity by genetically-modified dendritic cells' J. VIROL. vol. 75, no. 16, 2001, pages 7621 - 7628
LISZIEWICZ J. ET AL.: 'DermaVir: a novel topical vaccine for HIV/AIDS' J. INVEST DERMATOL. 2004, pages 1 - 10
LISZIEWICZ J. ET AL.: "Control of viral rebound through therapeutic immunisation with DermaVir" AIDS, vol. 19, 2005, pages 35-43,
J. LISZIEWICZ ET AL.: 'Control of HIV despite the discontinuation of antiretroviral therapy' NEW ENGLAND J. MED vol. 340, no. 21, 1999, pages 1683 - 1684


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).